拓扑异构酶Ⅱ和人类表皮生长因子受体在乳腺癌中的表达及意义

Expression and significance of TOP2A and HER2 in breast cancer

目的探讨拓扑异构酶Ⅱ(TOP2A)、人类表皮生长因子受体2(HER2)在乳腺癌中的表达及意义。方法选取2015年3月至2017年3月治疗的乳腺癌患者72例(乳腺癌组),同时选取60例乳腺纤维腺瘤患者作为对照组,采用免疫组化法检测TOP2A和HER2蛋白表达,检测TOP2A和HER2基因状态。结果乳腺癌组HER2、TOP2A蛋白阳性表达率及HER2基因扩增率分别为65.28%、69.44%和56.94%,明显高于对照组的6.67%、5.00%和3.33%(P<0.05);乳腺癌组和对照组TOP2A基因扩增率比较差异无统计学意义(P>0.05);有淋巴结转移、ER阴性、PR阴性患者HER2蛋白阳性表达率和HER2基因扩增率分别为87.10%和87.10%、90.00%和90.00%、92.00%和80.00%,明显高于无淋巴结转移、ER阳性、PR阳性患者的55.32%(P<0.05);PR阴性患者TOP2A蛋白阳性表达率为96.00%,明显高于PR阳性患者(P<0.05);HER2基因扩增患者TOP2A蛋白阳性表达率为85.37%,明显高于非扩增患者的48.39%(P<0.05);HER2基因扩增和非扩增患者TOP2A基因扩增率比较差异无统计学意义(P>0.05)。结论 TOP2A、HER2与乳腺癌临床病理特征有一定关系,且HER2基因扩增患者TOP2A蛋白阳性表达率高,值得进一步研究。

Objective To investigate the expression and significance of topoisomerase II（ TOP2 A）,human epidermal growth factor receptor 2（ HER2） in breast cancer. Methods Seventy-two patients with breast cancer who were treated in our hospital from March 2015 to March 2017 were enrolled as breast cancer group,at the same time,the other 60 patients with breast fibroadenoma were ebrolled as control group. The expression levels of TOP2 A and HER2 protein were detected by immunohistochemistry,moreover TOP2 A and HER2 gene status was detected by fluorescence in situ hybridization.Results The positive expression rates of HER2 and TOP2 A protein and the amplification rate of HER2 gene were 65. 28%,69. 44% and 56. 94%,respectively in breast cancer group,which were significantly higher than those in control group（ P 〈0. 05）. There was no significant difference in amplification rate of TOP2 A gene between breast cancer group and control group（ P 〉 0. 05）. The positive expression rate of HER2 protein and HER2 gene amplification rate in patients with lymph node metastasis,negative ER,negative patients PR were 87. 10% and 87. 10%,90% and 90%,92% and 80%,respectively,which were significantly higher than those of patients without lymph node metastasis,positive ER and positive PR（ P 〈0. 05）. Moreover the positive expression rate of TOP2 A protein in patients with negative PR was 96%,which was significantly higher than that in patients with positive PR（ P 〈 0. 05）. In addition the positive expression rate of TOP2 A protein in patients with HER2 gene amplification was 85. 37%,which was significantly higher than that in patients without HER2 gene amplification（ P 〈 0. 05）. There was no significant difference in TOP2 A gene amplification rate betweemn the patients with HER2 gene amplification and the patients without HER2 gene amplification（ P 〉 0. 05）. Conclusion TOP2 A and HER2 are related to the clinicopathological features of breast cancer at certain extent,moreover,the positive expression rate of TOP2 A protein in patients with HER2 gene amplification is higher,which needs to be researched further.